Lilly Tries to Buy Time
Executive Summary
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?